Multimodal analgesia targets pain transmission at multiple points along the nociceptive pathway using mechanistically distinct drug classes to achieve additive or synergistic pain relief while minimizing individual drug doses and side effects, particularly opioid-related adverse effects. Pain signaling involves four physiological processes: transduction (conversion of tissue injury into electrical signals via nociceptors through prostaglandin-sensitized ion channels), transmission (propagation along A-delta and C fibers through the dorsal root ganglion to the dorsal horn of the spinal cord), modulation (enhancement or inhibition of pain signals at the spinal and supraspinal levels), and perception (cortical processing of pain in the somatosensory cortex, anterior cingulate, and insular cortex). Non-opioid analgesics target transduction: NSAIDs and COX-2 inhibitors block cyclooxygenase-mediated prostaglandin synthesis at the site of tissue injury, reducing peripheral sensitization; acetaminophen acts centrally, likely through serotonergic descending inhibitory pathways and endocannabinoid system modulation. Gabapentinoids (gabapentin, pregabalin) bind the alpha-2-delta subunit of voltage-gated calcium channels in the dorsal horn, reducing excitatory neurotransmitter release and attenuating central sensitization — particularly effective for neuropathic pain. Local anesthetics (lidocaine, bupivacaine) block voltage-gated sodium channels, preventing action potential generation and...